tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

BONESUPPORT to Release Q3 2025 Interim Report with Conference Call

Story Highlights
BONESUPPORT to Release Q3 2025 Interim Report with Conference Call

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

BONESUPPORT HOLDING AB ( (SE:BONEX) ) has shared an announcement.

BONESUPPORT HOLDING AB announced it will release its Q3 2025 interim report on October 23, followed by a conference call and online presentation hosted by the CEO and CFO. This event is significant as it provides stakeholders with insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.

The most recent analyst rating on (SE:BONEX) stock is a Hold with a SEK297.00 price target. To see the full list of analyst forecasts on BONESUPPORT HOLDING AB stock, see the SE:BONEX Stock Forecast page.

More about BONESUPPORT HOLDING AB

BONESUPPORT HOLDING AB is a prominent company in the orthobiologics industry, specializing in the development and commercialization of innovative injectable bio-ceramic bone graft substitutes. These products, based on a patented technology platform, are designed to remodel into the patient’s own bone and have the capability of eluting drugs. The company, headquartered in Lund, Sweden, is actively involved in clinical studies to demonstrate the clinical and health economic benefits of its products.

Average Trading Volume: 152,741

Technical Sentiment Signal: Sell

Current Market Cap: SEK17.39B

For a thorough assessment of BONEX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1